Quotient Sciences has acquired Arcinova, a U.K.-based CDMO. Arcinova has 160 employees, and provides drug substance, drug product and bioanalysis services to more than 200 pharma/biopharma customers worldwide.   The acquisition expands Quotient’s services with drug substance, drug product and clinical testing capabilities, along with the 12-month drug development timeline delivered by Quotient’s flagship platform Translational Pharmaceutics.   “I’d like to congratulate the Arcinova team on b...